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Abstract
AIM: To determine the clinical impact of portal vein 
thrombosis in terms of both mortality and hepatic 
decompensations (variceal hemorrhage, ascites, por-
tosystemic encephalopathy) in adult patients with 
cirrhosis.
METHODS: We identified original articles reported 
through February 2015 in MEDLINE, Scopus, Science 
Citation Index, AMED, the Cochrane Library, and 
relevant examples available in the grey literature. Two 
independent reviewers screened all citations for inclu-
sion criteria and extracted summary data. Random 
effects odds ratios were calculated to obtain aggregate 
estimates of effect size across included studies, with 
95%CI.
RESULTS: A total of 226 citations were identified 
and reviewed, and 3 studies with 2436 participants 
were included in the meta-analysis of summary effect. 
Patients with portal vein thrombosis had an increased 
risk of mortality (OR = 1.62, 95%CI: 1.11-2.36, P  = 
0.01). Portal vein thrombosis was associated with an 
increased risk of ascites (OR = 2.52, 95%CI: 1.63-3.89, 
P  < 0.001). There was insufficient data available 
to determine the pooled effect on other markers of 
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decompensation including gastroesophageal variceal 
bleeding or hepatic encephalopathy. 
CONCLUSION: Portal vein thrombosis appears to 
increase mortality and ascites, however, the relatively 
small number of included studies limits more genera-
lizable conclusions. More trials with a direct comparison 
group are needed.
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Hepatic encephalopathy; Portal hypertension
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Core tip: Portal vein thrombosis (PVT) is a common 
complication of cirrhosis with resultant downstream 
hepatic decompensation and mortality. Treatment 
options carry risk and are not without complications. 
To date, there is a lack of systematic evidence on the 
clinical importance of PVT. We performed a systematic 
review and meta-analysis to determine the aggregate 
estimates of effect of PVT on hepatic decompensation 
and mortality. PVT appears to significantly increase 
mortality (OR = 1.62, 95%CI: 1.11-2.36) and ascites 
(OR = 2.52, 95%CI: 1.63-3.89), however, the small 
number of included studies limits more generalizable 
conclusions. More trials with a direct comparison group 
are needed.
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INTRODUCTION
Portal vein thrombosis (PVT) is defined as an obstruction 
of the portal vein or its branches, which include the 
splenic, superior mesenteric, and inferior mesenteric 
veins[1]. It is associated with numerous conditions 
including malignancy, myeloproliferative disorders, 
inflammatory conditions (such as pancreatitis), intra-
abdominal infections (such as secondary peritonitis), and 
cirrhosis[2,3]. PVT is common in patients with cirrhosis; 
over 30% of liver transplant recipients have PVT on direct 
explant examination at the time of transplant (LT)[2,4,5]. 
Incidence rates of PVT while variable, are reported to be 
as high as 16%[6]. The mechanism of PVT development 
in cirrhosis is multifactorial and is due to a combination 
of changes in liver architecture leading to impaired blood 
flow and endothelial cell activation, hypercoagulability, 
and the potential development of hepatocellular 
carcinoma (HCC)[7]. The presence of PVT appears to be 
associated with the severity of underlying liver disease 
and hepatic decompensation from a mechanistic stand-
point. However, the field of coagulation disorders and 
chronic liver disease is ever evolving and continues to 
generate controversy, in particular, when consideration is 
given to the impact of PVT on the development of hepatic 
decompensation. Multiple studies have been published 
indicating adverse clinical outcomes in the setting of 
PVT in both transplant and non-transplant populations, 
including hepatic decompensation, increased post-
transplant mortality, and decreased quality of life[7-10]. 
Others have argued that PVT does not affect clinically 
relevant outcomes[11]. Due to this uncertainty, we sought 
to determine the clinical impact of PVT on transplant free 
survival and hepatic decompensation in adult patients 
with cirrhosis. 
MATERIALS AND METHODS
Literature search strategy and study selection
The investigators systematically searched the published 
medical literature for observational studies and clinical 
trials that compared mortality or hepatic decompensation 
outcomes in cirrhosis patients with and without PVT. Pub-
lished studies were identified by searching the following 
electronic databases: MEDLINE, Scopus, Science Citation 
Index, AMED, and the Cochrane Library. The search 
criteria included all publications through February 2015 
with English language restriction. Electronic search 
criteria included the following terms or keywords: “portal 
vein thrombosis”, “mesenteric thrombosis”, “splanchnic 
thrombosis”, “cirrhosis”, “mortality”, “decompensation”, 
and “humans”. We reviewed the reference lists of 
included articles in order to identify articles missed in 
the database searches. Recent conference abstract lists 
and other relevant grey literature sources were also 
searched for examples of relevant studies using the 
same terms and keywords. Studies were excluded if PVT 
was associated with only malignancy, developed post-
procedure (surgery or interventional), were found in non-
cirrhotic patients with portal hypertension, were in LT-
only recipients, if no control/comparison group without 
PVT was included, or if survival was not analyzed. This 
study did not require institutional review board approval.
Data extraction
Two study personnel (Stine JG and Shah PM) inde-
pendently screened the abstracts and titles of all studies 
identified using the electronic and manual search 
criteria to identify studies meeting the inclusion criteria. 
Each study meeting requirements of the first-round 
inclusion criteria then underwent a full-text indepen-
dent review by both reviewers. Disagreements about 
inclusion between reviewers were resolved by follow-up 
consultation, and if necessary by a third clinical reviewer 
(Cornella CL). Two reviewers independently extracted 
the following data from each study that met inclusion 
criteria: patient characteristics (age, gender, MELD, 
and etiology of liver disease), study-level characteris-
tics (author, publication year, study design, enrollment 
period, target population, total number of enrolled 
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patents, and percentage of patients with PVT) and 
outcomes (mortality and hepatic decompensation). 
Primary and secondary outcomes
Mortality was the primary outcome assessed. Secondary 
outcomes included the presence of or development of 
new gastroesophageal variceal bleeding, ascites, hepatic 
encephalopathy, and an aggregate measure of the 
occurrence of any of these three hepatic decompensation 
outcomes. 
Study quality and risk of bias assessment
The quality of observational studies was assessed 
using the methods described by Stroup et al[12]. Only 
studies deemed high-quality by the investigators were 
included in the analysis. The Newcastle-Ottowa Quality 
Assessment for Cohort Studies scale[13] was used to 
further characterize the quality of studies based on 
selection of study groups, comparability of groups, and 
ascertainment of outcome. The studies are rated on 
an 8-point scale separated by the three broad sections 
delineated above. 
Statistical analysis
Descriptive analysis of the studies identified, excluded, 
and included, and meta-analysis of the reported study 
effect measures, was conducted utilizing review manager 
software (Rev-Man version 5.3; Copenhagen; The Nordic 
Cochrane Centre; The Cochrane Collaboration; 2014). 
We estimated pooled ORs and calculated corresponding 
95%CIs using DerSimonian and Laird random-effects 
models, which account for both between and within 
study variability given that the included studies were 
not functionally identical[14,15]. Between study variability 
was separately assessed using the Cochran’s Q statistic 
(with P < 0.05 considered significant). The proportion of 
heterogeneity accounted for by between-study variability 
was estimated using the I2 index and adjudicated to be 
significant if I2 was > 75%[14,15]. A post-hoc funnel plot 
was created to assess for the presence or absence of 
publication bias.
RESULTS
Included studies 
The electronic search criteria identified 226 studies. 
After ensuring no duplicates were present, we screened 
titles and abstracts. The full text of eleven studies was 
assessed for eligibility. Following the qualitative systematic 
review process, three observational studies met the 
inclusion criteria for the current meta-analysis[7,16,17]. 
Of these, two were retrospective[7,17]. The third study 
followed a prospective cohort of patients[16]. No additional 
studies were appropriate for inclusion based on our 
a-priori determined inclusion and exclusion criteria. Nery 
et al[11] recently published a multicenter prospective 
series of 1243 adult patients with cirrhosis without 
baseline PVT in France and Belgium. About 118 patients 
developed de novo PVT during a median follow-up period 
of 47 mo. This study, while initially considered in full-
text review, was excluded specifically because absolute 
numbers for mortality or individual types of hepatic 
decompensation were not provided; rather, univariate 
and multivariable analysis P-values were provided only 
and only a composite of hepatic decompensation was 
given in absolute number.
The 3 eligible reports evaluated cirrhotic patients that 
did not initially have PVT, but developed it sometime over 
the study period. They each excluded patients with HCC 
and prior transplant. All 3 studies evaluated long-term 
outcomes in cirrhotic patients with PVT compared to 
cirrhotic patients without PVT. Study level characteristics 
are found in Table 1. A summary of the search results is 
presented in Figure 1, reflecting the reporting standards 
of the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses[18]. 
The Englesbe et al[7] study assessed a total of 3295 
(148 with PVT and 3147 without PVT) cirrhotic patients 
between 1995-2007. The study assessed patients 
that were being evaluated as candidates for liver trans-
plantation that had thrombus in the main portal vein 
only. Patients with partial thrombus or thrombi in portal 
vein branches, without extension into the main portal 
vein were excluded. The Maruyama et al[17] article 
evaluated a total of 150 patients with viral hepatitis, 42 
had PVT (and 108 did not have PVT). The study by John 
et al[16] found 290 patients with cirrhosis, 70 of these 
had PVT and 220 did not. Notably, both the Maruyama 
et al[17] and John et al[16] articles specified patients with 
complete and partial thrombus, unlike the Englesbe 
study[7]. 
In total, the three studies included 3735 cirrhotic 
patients, 260 of which had PVT. Lengths of follow-up 
ranged from less than one month to 136 mo, with mean 
follow-ups ranging from 25 mo to 50 mo. Baseline 
demographic characteristics were similar between PVT 
and non-PVT groups in all 3 studies. There were no 
differences in regards to race, age, gender, causes of 
cirrhosis, or model for end stage liver disease (MELD) 
scores. Demographic and etiologic characteristics of the 
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Table 1  Study level characteristics  n  (%)
Ref. Date published Dates enrolled Enrollment PVT Death - no PVT Death - PVT
John et al[16] 2013 2004-2009   290     70 (24.1)     62 (28.2) 24 (34.3)
Maruyama et al[17] 2013 1998-2009   150     42 (28.0)     21 (19.4)   9 (21.4)
Englesbe et al[7] 2010 1995-2007 3295 148 (4.5) 1171 (37.2) 81 (54.7)
PVT: Portal vein thrombosis.
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Maruyama et al[17] and John et al[16] both received 6/8. 
The potential for publication bias was assessed using a 
funnel plot of the relationship between reported effect 
variance SE(log[OR]) and the reported study OR. 
The plot illustrates the lack of evidence for potential 
publication bias in the three studies-the study with the 
largest effect size is the largest study included while the 
smaller studies have lower effect sizes (Figure 2).
Portal vein thrombosis and mortality
The Englesbe et al[7] article demonstrated an incidence 
rate of 4.5% for PVT. The patients with PVT were at 
significantly higher risk of mortality with an OR of 
2.04 (95%CI: 1.46-2.84) (Figure 3) Conversely, the 
Maruyama et al[17] and John et al[16] studies found higher 
rates of mortality between PVT and non-PVT subjects. 
The OR for mortality for PVT in both studies were 1.13 
and 1.27, respectively but these differences were non-
significant. Pooled analysis of the results reported across 
all 3 studies demonstrates a significantly increased 
risk of mortality in PVT patients (OR = 1.62, 95%CI: 
1.11-2.36, P = 0.01). The Cochran’s Q statistic was non-
significant at P = 0.23 and I2 = 32%, demonstrating 
non-significant heterogeneity of effects reported across 
studies.  
Portal vein thrombosis and hepatic decompensation
Secondary outcomes included episodes of hepatic 
decompensation, including individual cases of ascites, 
variceal bleeding, or portosystemic encephalopathy. 
Both John et al[16] and Maruyama et al[17] demonstrated 
similar effects of PVT on ascites development. John 
et al[16] showed an OR of 1.51 (95%CI: 0.87-2.60) 
compared to an OR of 7.46 (95%CI: 3.38-16.45) in the 
Maruyama et al[17] study (Figure 4). The Englesbe et al[7] 
study was excluded from this portion of analysis since 
they did not report on rates of hepatic decompensation. 
When the pooled OR was evaluated using random-
effects modeling, PVT continued to have statistically 
patients included in each studies are summarized in 
Table 2.
Bias assessment
All 3 studies include cohorts drawn from their abdominal 
transplant clinic population. The patients were truly 
representative of the average transplant population. 
Exposed and unexposed patients (patients with cirrhosis 
with spontaneous PVT and those without PVT) were 
all drawn from their transplant clinic population and all 
information was obtained through medical records in the 
three studies. The Englesbe et al[7] study controlled for 
PVT along with MELD, age, and presence of hepatitis C 
virus in a multivariable logistic regression with survival 
as the outcome. The Maruyama et al[17] study does not 
include a model controlling for covariates. The John et 
al[16] study does control for ascites and renal function, 
however this study created a multivariable model to 
identify predictors for PVT development. All three studies 
had widely variable amounts of follow-up and there is 
no information available on patients lost to follow-up 
for any of the studies. Based on these characteristics, 
the Englesbe et al[7] study received a score of 7/8, while 
216 records identified through database searching
10 records identified through other sources
226 records screened
11 full text articles reviewed
3 studies included in review
215 records excluded
8 full text articles excluded
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Figure 1  The preferred reporting items for systematic reviews and meta-analyses diagram. About 226 records were screened in aggregate; 11 full text articles 
were reviewed; 3 studies met inclusion criteria.
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Figure 2  Funnel plot assessing publication bias. No significant publication 
bias was observed in this study.
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significant higher odds of hepatic decompensation (OR 
= 2.52, 95%CI: 1.63-3.89, P < 0.001). The Cochran’s 
Q statistic and I2 were both significant for heterogeneity 
in this analysis. There was insufficient data available 
to determine the pooled effect on other markers of 
decompensation including gastroesophageal variceal 
bleeding or hepatic encephalopathy.
DISCUSSION 
Our systematic review and meta-analysis is the first 
study to offer a pooled estimate and quantitative 
assessment of the clinical impact of PVT in terms of 
both mortality and hepatic decompensation. We have 
demonstrated a significantly increased rate of mortality 
for patients with cirrhosis and PVT when compared to 
those patients without PVT. This finding is important 
because PVT is a common finding in patients with 
cirrhosis[4,6,19] and one that significantly impairs quality of 
life and post-LT outcomes[7-9]. Several risk factors have 
been suggested to increase the risk of PVT in patients 
awaiting liver transplantation, including non-alcoholic 
steatohepatitis[20]. 
The risk of hepatic decompensation with ascites for 
patients with cirrhosis was also significantly greater 
in the presence of PVT. Evaluating a pooled estimate 
Table 2  Patient level characteristics  n  (%)
Englesbe 20101 John 20132 Maruyama 20133
No PVT (n  = 3147) PVT (n  = 148) No PVT (n  = 220) PVT (n  = 70) No PVT (n  = 108) PVT (n  = 42) 
Sex (M/F) 1905/1242 91/57 144/76 42/28 63/45 22/20
Race
   Black  218 (6.9)   7 (4.7) - - - -
   White - -  184 (83.6) 60 (85.7) - -
   Other  2545 (80.9) 131 (88.5) - -
"Nonblack" "Nonblack" - -
Etiology
   AIH 95 (3)   8 (5.4) - - - -
   Biliary/cholestatic  173 (5.4)   7 (5.4) 24 (11) 5 (7.1) - -
   Alcohol    672 (21.4)   31 (20.9)    37 (16.9) 5 (7.1) - -
   Viral  1253 (39.8)   50 (34.1)    62 (28.3) 16 (27.1) 108 42
   Cryptogenic/NASH    72 (2.3) 0 35 (16) 12 (17.1) - -
   Other    449 (14.3)   22 (14.9)    37 (16.9) 20 (28.6) - -
Age (yr)   51.5 ± 11.2   50.9 ± 10.8 55.8 ± 9.1 58.4 ± 8.8 63.3 ± 8.68 62.4 ± 11
MELD 12.1 ± 7.2 13.3 ± 8.3 13.8 ± 4.5 14.9 ± 5.9      10.2     10.6
1Presence of PVT at time of initial transplant evaluation or during the pre-transplant period; 2PVT category includes patients with PVT at baseline (n = 47) 
and those that developed new PVT during the study period (n = 23); 3Study only assessed patients with viral hepatitis. No data reported for race. PVT: 
Portal vein thrombosis; MELD: Model for end stage liver disease; NASH: Non-alcoholic steatohepatitis; M/F: Male/female; AIH: Autoimmune hepatitis.
PVT No PVT Odds ratio Odds ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95%CI M-H, random, 95%CI
Englesbe et al   81 148 1171 3147   54.8% 2.04 (1.46, 2.84)
John et al   24   70     64   220   29.7% 1.27 (0.72, 2.26)
Maruyama et al     9   42     21   108   15.4% 1.13 (0.47, 2.72)
Total (95%CI) 260 3475 100.0% 1.62 (1.11, 2.36)
Total events 114 1256
Heterogeneity: Tau2 = 0.04; χ 2 = 2.96, df = 2 (P  = 0.23); I 2 = 32%
Test for overall effect: Z  = 2.50 (P  = 0.01) 0.01                  0.1                  1                    10                  100
Favours no PVT                       Favours PVT
Figure 3  Portal vein thrombosis and mortality. PVT is associated with an increased pooled risk of death in the absence of significant heterogeneity. PVT: Portal 
vein thrombosis.
PVT No PVT Odds ratio Odds ratio
Study or subgroup Events Total Events Total Weight M-H, fixed, 95%CI M-H, fixed, 95%CI
John et al  2013 31   70 76 220   83.0% 1.51 (0.87, 2.60)
Maruyama et al  2013 27   42 21 108   17.0%   7.46 (3.38, 16.45)
Total (95%CI) 112 328 100.0% 2.52 (1.63, 3.89)
Total events 58 97
Heterogeneity: χ 2 = 10.63, df = 1 (P  = 0.001); I 2 = 91%
Test for overall effect: Z  = 4.17 (P  < 0.0001) 0.05         0.2              1               5            20
Favours no PVT               Favours PVT
Figure 4  Portal vein thrombosis and ascites. PVT is associated with an increased pooled risk of hepatic decompensation manifested as ascites. This conclusion 
may be limited by heterogeneity in the included studies. PVT: Portal vein thrombosis.
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of risk for gastroesophageal variceal hemorrhage or 
ascites resulting from PVT could not be performed due 
to the lack of data reporting by the included studies. 
While this has been shown in other studies, these were 
not included due to a lack of a comparison group.
PVT appears to increase mortality and hepatic 
decompensation (composite as well as variceal hemorr-
hage and ascites), however, the relatively small number 
of included studies limits generalizable conclusions. Our 
study has several other limitations. Multiple studies with 
a large number of patients were excluded due to a lack 
of a comparison group, and our literature search revealed 
a general lack of randomized controlled trials within 
the context of PVT. The large multicenter prospective 
study by Nery et al[11] was specifically excluded due 
to a lack of absolute numbers and component hepatic 
decompensation assessment. The inclusion of only 
three studies also limits the systematic assessment 
for publication bias and may also have resulted in the 
large degree of heterogeneity seen in calculation of the 
pooled measure of effect for PVT and the development of 
ascites.
Regardless, this current review represents the 
best available summary of the evidence to date and 
highlights a significant need for future research around 
the implications of PVT, especially prospective studies 
with a direct comparator group. Safety and efficacy data 
on both prevention and treatment of PVT is in general 
lacking. Villa et al[21] recently published their unblinded 
randomized, single center experience having found that 
daily prophylactic dosing of low molecular weight heparin 
(the equivalent of 40 mg/d) for twelve months prevented 
the development of PVT in patients with compensated 
cirrhosis. While the study was terminated at 48 wk, 
the effect persisted through follow-up at 5 years when 
compared to standard of care[21]. Additionally, the authors 
demonstrated less hepatic decompensation in the low 
molecular weight heparin arm (P < 0.0001) and a more 
importantly, a significant survival benefit[21]. Building 
on this work, Cui et al[22] published their single center 
randomized trial of 65 patients investigating therapeutic 
doses of low-molecular weight heparin (1 mg/kg every 
twelve hours or 1.5 mg/kg daily), where 78.5% (n = 51) 
responded to treatment with either complete or partial 
recanalization at 6 mo after starting therapy. These 
responders had regression of their liver disease when 
compared directly to the 14 non-responders. Similar to 
Villa et al[21], Cui et al[22] found no episodes of variceal 
hemorrhage, however, they did find much higher rates 
of non-variceal bleeding (6.4%-23.5%). While this 
study has several limitations including its generalizability 
as it only enrolled hepatitis B patients in China, it is 
nonetheless promising. With the development of new oral 
anticoagulants, the promise of treatment and possibly 
prevention is becoming a reality[23]. More rigorous 
study is needed in the field of coagulation disorders 
in a randomized, placebo controlled interventional 
or preventative trial with a direct comparator group 
using either heparin based or new direct acting oral 
anticoagulant therapy. 
In conclusion, PVT appears to increase mortality 
and hepatic decompensation from ascites, however, 
the relatively small number of included studies limits 
generalizable conclusions and contributes significant 
heterogeneity in the pooled measures of effect. More 
prospective, randomized placebo controlled trials with a 
direct comparator group are needed.
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